This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). It is expected to expedite the development of a wide range of new therapeutics using the small non-coding area of the genome that is not explored.
The biotech said its first acquisition, an $85 million purchase of Japanese company OriCiro Genomics, will hand it better tools to make a key building block of messenger RNA.
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Their platform identifies which regRNAs control the specific gene of interest.
Discover how genomics is transforming cancer research through the study of DNA, RNA, and ctDNA. Learn about the latest breakthroughs in the field in this insightful short read.
That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey. "For the first time in history, medicine has become information."
Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.
2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.
David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.
Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on.
Credit: The Wistar Institute PHILADELPHIA — (March 12, 2021) — Scientists at The Wistar Institute identified a new function of ADAR1, a protein responsible for RNA editing, discovering that the ADAR1p110 isoform regulates genome […].
A clinical research team from the University of Hong Kong (HKUMed) has used amniotic fluid cells obtained during 16-24 weeks of pregnancy as a novel sample type for RNA-sequencing in prenatal diagnosis to help more families with tailored clinical management. The findings have been published in the journal, npj Genomic Medicine.
In the world of rare genetic diseases, exome and genome sequencing are two powerful tools used to make a diagnosis. A recent addition to the toolkit, RNA sequencing, has been demonstrated to help researchers narrow down disease candidate variants identified first on exome and genome sequencing.
The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. Research Instruments is the main distributor for genomic and life science research products in the region.
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on. Visit our website: www.rna-editing-summit.com.
Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. First, a novel approach was used that didn’t require traditional vaccine production in cell cultures or eggs. 1455NO-HEALTH-CORONAVIRUS_VACCINES_PFIZER_O_.
The human genome was sequenced in 2003. It is now possible to treat diseases with gene therapy, antisense oligonucleotides, messenger RNA (mRNA), noncoding RNA (known as small interfering RNA, or siRNA), and other gene-based modalities. That said, a lot has changed in science and drug development since 1983.
— Each simple RNA virus has a genome, its “native RNA.” This genome dictates how the virus replicates in cells to eventually cause disease. The genome also has the code for making a capsid, the protein shell of a virus that encapsulates the genome and protects it like a nanocontainer. RIVERSIDE, Calif.
Genome sequencing has historically been classified into DNA sequencing and RNA sequencing. DNA sequencing generates data that is very robust, reproducible, insightful, and can be applied to genes having different expression level by selecting genomic region. between 2022 and 2035.
10X Genomics just agreed to acquire ReadCoor, Inc., The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology. an innovator in the nascent field of in situ technology.
Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research PITTSBURGH–(BUSINESS WIRE)–#RNA–Ocean Genomics (Pittsburgh, PA), a world leader in AI-based gene expression analysis and RNA biomarker … Continue (..)
Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer Credit: St. Jude Children’s Research Hospital St.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Outsmarting cancer with RNA, ‘genome-tuning’ drugs and other gene-altering therapies.Outsmarting cancer with RNA, ‘genome-tuning’ drugs and other gene-altering therapies arlene.weintraub Tue, 06/22/2021 (..)
29, 2020– A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19. Credit: American Thoracic Society Oct.
The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it.
. — To the untrained eye, the loops, kinks and folds in the single strand of RNA that makes up the coronavirus genome look like a jumble of spaghetti or tangled yarn. But to researchers like Amanda Hargrove, a chemistry professor at Duke University, the complex shapes that RNA takes on as it folds […].
Nowakowski An international collaboration among researchers from Finland, Sweden, UK and the USA has captured ribosomes translating messenger RNA expressed from the maternally inherited mitochondrial genome. Amunts and D.
The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA. It edits genes by precisely cutting DNA, then allowing natural DNA repair processes to take over.
Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on.
Genomic Testing Cooperative Completes New York State Approval and Medicare (Palmetto) Coverage for all DNA and RNA Tests Offered for Molecular Profiling of Hematologic and Solid Tumors Genomic Testing Cooperative Completes New York State Approval and Medicare (Palmetto) Coverage for … Continue reading →
Scientists at Goethe University within the international consortium COVID19-NMR refine previous 2D models The genetic code of the SARS-CoV2 virus is exactly 29,902 characters long, strung through a long RNA molecule. It contains the information for the production of 27 proteins.
As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.
Coronaviruses, like Covid-19, are a notorious group of infectious agents that include a large class of viruses with RNAgenomes, similar to the human DNA genome, that depend on well-organised protein structures crucial for viral growth and replication.
Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA Transcriptome Data and on the Use of Liquid Biopsy Genomic Testing Cooperative to Present data at the American Society … Continue reading →
It is also looking to expand its RNA silencing research, potentially bringing it into competition with biotech heavyweights such as Alnylam, something that Mortazavi focused on during his long time at the helm of Silence Therapeutics. The company has considerably more cash than at the start of the year – on 31 July it had £15.1
The Duke researchers developed statistical methods to identify adaptive changes that arose specifically in the SARS-CoV-2 genome in humans, but not in closely related coronaviruses found in bats and pangolins. Moreover, Berrio says the changes likely affected the folding and function of viral RNA.
In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Using machine learning to identify ancient RNA viruses in the human genome.A team of researchers affiliated with multiple institutions in Japan has used machine learning algorithms to … Continue reading →
Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018.
Now, researchers reporting in ACS Central Science have identified small molecules that target a structure within the RNAgenome […]. Scientists are fighting back with multiple strategies, including vaccines, repurposed drugs developed for other diseases and brand-new therapies.
Moderna Genomics general manager and chief scientific officer Eric Huang said: “Through our collaboration with Life Edit, we hope to harness the power of gene editing technologies as part of our broader research and development engine, helping to advance our mission and deliver on the promise of mRNA.”
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scaling up genome editing in tiny worms.Understanding the effects of specific mutations in gene regulatory regions—the sections of DNA and RNA that turn genes on and off—is … Continue reading →
Researchers at the Hong Kong University of Science and Technology (HKUST) developed a novel technology which allows genomic DNA and RNA sequencing to be carried out simultaneously in single cells of both frozen and fresh tissues, and identified rare brain tumor cell "spies" disguised as normal cells with this method.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content